Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

In Vivo CAR-T Development Service with Lipid Nanoparticle Technology

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs offers an advanced In Vivo CAR-T Development Service powered by Lipid Nanoparticle (LNP) Technology to help streamline and scale next-generation cell-therapy programs. Our platform enables the direct in vivo programming of functional CAR-T cells through optimized LNP formulations engineered for targeted delivery, high nucleic acid payload efficiency, and controlled expression kinetics. We provide end-to-end support, including CAR construct design, LNP development and characterization, targeting ligand integration, in vivo delivery optimization, expression durability assessment, and preclinical validation. This solution minimizes reliance on complex ex vivo manufacturing, improves CAR expression consistency, and accelerates translational progress for innovative in vivo CAR-T therapeutics.

Introduction

LNP systems enable direct in vivo CAR expression in circulating T cells through the optimization of nucleic acid design and ionizable lipid chemistry. Published studies demonstrate that optimized ionizable LNPs can transiently program immune cells, enabling precise CAR expression and functional activity without ex vivo manipulation. Optimized lipid and payload design enables controlled expression, enhanced safety, and strong clinical potential for cancer and immune therapies.

Fig.1 Core strengths of the mRNA-LNP platform for CAR-T cell engineering. (OA Literature) Fig.1 Key advantages of mRNA-LNP-based CAR-T cell engineering.¹

Creative Biolabs' Service

Creative Biolabs provides a comprehensive service portfolio enabling clients to develop, evaluate, and optimize in vivo–programmed CAR-T therapies using advanced lipid nanoparticle (LNP) delivery systems. Our services integrate nucleic-acid engineering, precision nanoparticle formulation, and in vivo functional validation, supporting seamless progression from concept to preclinical readiness. We systematically evaluate particle size distribution, encapsulation efficiency, membrane fusion properties, and in vitro delivery performance across relevant cell types. Whether you aim to evaluate feasibility, optimize a lead candidate, or generate preclinical evidence for regulatory submission, Creative Biolabs delivers flexible, scientifically rigorous, and fully customizable service solutions.

Discover How We Can Help - Request a Consultation.

Technology Platforms

Payload Types

Modified mRNA (most common): Enables transient CAR expression without genomic integration, offering a favorable safety profile.

Self-amplifying RNA (saRNA): Requires lower doses and may support more durable expression; currently under active exploration.

DNA: Allows longer-term or permanent expression but carries higher safety and regulatory risks.

Key Elements of LNP Formulation

Ionizable lipids drive nucleic acid encapsulation and endosomal release through pH-responsive behavior.

Helper lipids (DOPE, cholesterol, DSPC) and PEG-lipids tune particle stability, circulation, and cellular uptake. Adjusting lipid compositions can shift tissue tropism.

Cell-Targeting Strategies

Antibody/ligand-modified LNPs enable selective delivery to defined T-cell subsets by decorating LNP surfaces with targeting antibodies or ligands.

Major Technical Workflow

Workflow of In Vivo CAR-T Development with Lipid Nanoparticle Technology. (Creative Biolabs Original)

Final Deliverables:

LNP Characterization Dossier: Particle size, composition, encapsulation efficiency, and stability.

Customized Technical Recommendations: Formulation guidance, dosing strategies, and risk-mitigation considerations.

Key Advantages

Comprehensive end-to-end support for in vivo CAR-T engineering using advanced LNP delivery platforms, covering discovery, optimization, and preclinical evaluation.
Custom-formulated LNP systems, including ionizable lipids, helper lipids, and PEG-lipids, rationally designed to enhance stability, biodistribution, and T-cell–specific transfection efficiency.
Rigorous quality evaluation, including particle size distribution, encapsulation efficiency, sterility testing, and activity assessment compliant with high industrial standards.

FAQs

How do LNPs ensure targeted delivery to T cells?

Customizable lipid composition and optional surface ligands can enhance selective uptake. Additional optimization can further improve targeting efficiency depending on your model system.

Can the system support different CAR formats?

Yes. We support standard, modular, and co-stimulatory CAR architectures and can optimize payloads for varied expression windows.

What types of in vivo models are available?

We offer immunocompetent, xenograft, and humanized models to match your scientific and translational goals.

Is repeated dosing feasible?

LNP-based platforms support repeatable administration, allowing titration of expression or multi-cycle efficacy evaluation.

Partner With Us

Creative Biolabs brings extensive expertise in nanoparticle formulation, in vivo gene delivery, and CAR design. Our multidisciplinary engineering teams provide fully integrated support, from payload creation to in vivo testing, ensuring robust, reproducible outcomes. Our service platform is structured to provide exceptional flexibility, allowing rapid adaptation to new targets or therapeutic modalities. Connect with our experts to learn more and explore your project needs.

Reference

Meng, Sikun et al. "In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA Vaccines." International journal of molecular sciences vol. 26,7 3119. 28 Mar. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms26073119

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.